Silencing NACK by siRNA inhibits tumorigenesis in non-small cell lung cancer via targeting Notch1 signaling pathway

RANRAN KONG1, JIE FENG2, YUEFENG MA1, BIN ZHOU1, SHAOMIN LI1, WEI ZHANG1, JIANTAO JIANG1, JIN ZHANG1, ZHE QIAO1, TING ZHANG2, QUANJIN ZANG3 and XIJING HE3

1Department of Thoracic Surgery, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004; 2Department of Nephrology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061; 3Second Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, P.R. China

Received October 30, 2015; Accepted December 8, 2015

DOI: 10.3892/or.2016.4552

Abstract. Non-small cell lung cancer (NSCLC) is the most common type of lung tumor with poor prognosis, in which the Notch signaling pathway plays an important role. Notch activation complex kinase (NACK) has been reported both as a co-activator and a target gene of the Notch pathway. However, the molecular mechanism of NACK in NSCLC still remains unknown. In this study, the expression of NACK was analyzed in 35 paired NSCLC tumor samples and 2 NSCLC cell lines. MTT assay, cell migration assay, cell invasion assay, flow cytometry assay, and xenograft model were employed to detect the effect of NACK knockdown on the cell proliferation, metastasis, invasion and apoptosis of NSCLC. The relationship between NACK and Notch1 signaling pathway in NSCLC cells was assessed by western blot and luciferase reporter assay. We found that the expression of NACK in the NSCLC tissues and lung cancer cells were significantly increased. High level of NACK expression is remarkable associated with tumor differentiation, lymphatic metastasis, clinical stage and poor survival prognosis. The interference of NACK significantly inhibited cell proliferation, invasion and metastasis through inducing apoptosis in NSCLC cells. The transcriptional activity of related Notch1 target genes were significantly suppressed resulting from NACK knockdown. This study demonstrates that interference of NACK inhibits NSCLC progression through Notch1 signaling pathway and targeting NACK may be an effective approach for NSCLC therapy.

Introduction

Lung cancer is one of the leading causes of cancer-related mobility worldwide affecting millions of people every year (1,2). Lung cancer consists of two major types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which NSCLC account for 80% of them (3). Though various therapeutic agents for the treatment of NSCLC have been developed (4), poor prognosis was always discovered in patients on account of the frequent metastasizing characteristic of this malignancy (5).

The Notch signaling pathway has been identified as critical in governing cell fate determination by directly regulating transcriptional programs, including differentiation, proliferation, self-renewal, and apoptosis (6-8). Notch-1 signaling is activated when the complex of ligand and receptor binding is formed between directly contacting cells (9,10). Then Notch1 is cleaved by r-secretase and translocates the Notch-1 intracellular domain (NICD) from the plasma membrane into the nucleus to regulate related target genes including hairy enhance of split (Hes) family and hairy enhancer of split related with YRPW motif (Hey) family (11,12). Previous studies have reported that aberrant activation of Notch could cause a variety of solid malignancies including ovarian, breast, lung, and renal cancer, suggesting Notch may be an attractive target for therapeutic intervention in cancer (13,14).

Notch activation complex kinase (NACK) is the first identified as both a co-activator and a target gene of the Notch pathway. NACK regulates Notch transcriptional activity by interaction with the Notch transcriptional activation complex on DNA, which is required for Notch-mediated tumorigenesis (15). Recent studies have showed that knockdown of NACK resulted in inhibiting tumor growth in human esophageal carcinoma cells (15). However, the role and underlying mechanism of NACK in NSCLC still remains unknown.

In the present study, we analyzed the expression of NACK among NSCLC patients, and further investigated the role of NACK on tumor growth of NSCLC by small RNA interference method both in vitro and in vivo. We found that NACK expression was significantly increased in NSCLC tumors and cell lines. High NACK expression was associated with...
supplemented with 10% FBS (Hyclone, Logan, UT, USA), and were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% penicillin/streptomycin (Sigma-Aldrich, ON, Canada). Cells reagents were purchased from Invitrogen and supplied with 1% GeneChem Co., Bank (Shanghai, China). All cell culture epithelial cell line (NHBE) were obtained from the Shanghai cell lines A549 and H1299 and normal human bronchial Xi’an Jiaotong University.

Materials and methods

Tissue sample collection. In this study, NSCLC tumor tissues and paired adjacent normal tissues were obtained from 35 patients who underwent percutaneous lung puncture or biopsy of lung cancer tissue at The Second Affiliated Hospital of Xi’an Jiaotong University (Xi’an, China) between October 2013 and May 2014. All NSCLC cases were clinically and pathologically confirmed by two independent experts. All tissues were frozen at -80˚C for further analysis. The follow-up data for 60 months were recorded by communicating with the patients or their relatives, the median duration of follow-up was 59 months (range, 1-60 months). Informed consent was obtained from each patient, and this study was approved by the Human Ethics Committee of Second Affiliated Hospital of Xi’an Jiaotong University.

Cell lines and cell culture. The human lung adenocarcinoma cell lines A549 and H1299 and normal human bronchial epithelial cell line (NHBE) were obtained from the Shanghai GeneChem Co., Bank (Shanghai, China). All cell culture reagents were purchased from Invitrogen and supplied with 1% penicillin/streptomycin (Sigma-Aldrich, ON, Canada). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (Hyclone, Logan, UT, USA), and maintained in monolayer culture at 37˚C in an incubator of humidified air with 5% CO₂.

Plasmid construction and transient transfection of NSCLC cell lines. For NACK, the sequences for siRNA were design as follows: sense strand, 5’-UCG CAU UGA CCA UUC AAA CUG GUG G-3’ and antisense, 5’-CCA CCC GUU UGA AUG GUC AUA GGC A-3’. The scramble siRNA was random sequenced by Blast website. The cells were harvested at 48 h post-transfection. A549 and H1299 cells were used in this experiment. Twenty-four hours before transfection, 1x10⁴ cells/well, in 5 ml medium, were plated in 60 mm dish (Nunc; Thermo Fisher Scientific, Waltham, MA, USA), and then transfected with plasmids of NACK-siRNA or scramble siRNA as negative control using Lipofectamine 2000 as described in the manufacturer’s instruction.

Luciferase reporter assay. For reporter assay, A549 and H1299 cells were cultured in 24-well plates. Hes1-luciferase reporter plasmids were constructed by subcloning the 5-upsteam elements of human Hes1 into the pGL3-enhancer vector (Promega, Madison, WI, USA). Hes1 promoter-specific primers (-747+66): Forward, 5’-CGA GCT CAG CGG CAA CTT TAG ATG TG-3’; and reverse, 5’-CCC AAG CTT GTT GAC ACT GGC TGG GGT A-3’. After 24 h, the cells were co-transfected with the siRNA expression plasmid targeting NACK (NACK siRNA). Forty-eight hours later, luciferase activities were measured using Dual-Luciferase Reporter Assay system (Promega) according to manufacturer’s instructions. Firefly luciferase activity was normalized to Renilla luciferase activity.

RNA extraction and quantitative RT-PCR analysis. Total RNA was isolated from cells or tissues by TRIzol reagent (15596-026; Life Technologies) following the manufacturer’s instructions. Quantitative real-time reverse transcriptase-PCR assay (qRT-PCR) was performed using a SYBR-Green method with a Master Mix buffer system. Gene expression in human was normalized to GAPDH. The primers sequences were as follows: GAPDH forward, 5’-GGG CCT CAA GTG AGC GGA C-3’ and reverse, 5’-GGT GAG GGG TCG AGA AGT GA-3’; Hes1 forward, 5’-GGG CCT CAA GTG AGC GGA C-3’ and reverse, 5’-GGG CCT CAA GTG AGC GGA C-3’; Notch1 forward, 5’-GGG CCT CAA GTG AGC GGA C-3’ and reverse, 5’-GGG CCT CAA GTG AGC GGA C-3’; and HeyL forward, 5’-AGA TGG CAT CAA CAG TGA CCG CGC-3’ and reverse, 5’-CCA GGC TGC TAC CCA ATC CAA C-3’. The PCR conditions were as follows: 95˚C for 2 min, 95˚C for 15 sec, 60˚C for 30 sec for 40 cycles. The relative expression levels were calculated by the value of 2-ΔΔCt. All experiments were repeated at least three times.

Western blotting. The tissues and cells were washed twice with ice-cold PBS and lysed in RIPA lysis buffer (Solarbio, Beijing, China). The proteins were separated on SDS-polyacrylamide gels (SDS-PAGE) and electrophoretically transferred to PVDF membranes (Roche Diagnostics). Then the membranes were blocked in 5% milk, and incubated with the appropriate primary antibody overnight. The primary antibodies NACK (1:1,000; AbMax Company, China), Notch1 (1:1,000), Hes1 (1:1,000), and HeyL (1:1,000) (all from Abcam, UK), were incubated with HRP-conjugated secondary antibodies (Abcam) at 1:1,000 for 1 h, then the protein bands were detected using the enhanced chemiluminescence detection system (Pierce; Thermo Scientific, Rockford, IL, USA).

Cell proliferation assay. The proliferation of NSCLC cells was evaluated by Cell Counting Kit-8 (CCK-8) assay (Beyotime, Shanghai, China) according to manufacturer’s instruction. Briefly, cells transfected with negative-siRNA or NACK-siRNA were seeded into a 96-well plate (100 µl/well) and incubated at 37˚C, 5% CO₂ for 5 days. CCK-8 (10%) was added to the well at 24 h intervals and maintained for 2 h according to the manufacturer’s protocol, and then the absorbance was measured at 450 nm by a microplate reader (BioTek ELx800; BioTek, USA).

Colony formation assay. Non-small cell lung cancer cells (A549 and H1299) were transfected with negative-siRNA or NACK-siRNA for 24 h, then the transfected cells were resuspended, counted and seeded at a density of 600 cells/well in a 6-well plate. The cells were continually cultured for 10 days with a change of media every other day. On day 10, cells were fixed with 3.7% methanol, stained with 0.1% crystal violet the number of colonies were counted under a microscope (Olympus, Beijing, China).
are of Migration and invasion assays. Cell motility was assessed by migration and invasion assays. A 24-well Transwell insert containing a pore size of 8 µm polycarbonate membrane (Corning, Inc., Corning, NY, USA) was used to determine the effect of NACK on A549 and H1299 migration and invasion in vitro. Briefly, the transfected cells were cultured in serum-free medium for 12 h, then cells were resuspended in serum-free medium and placed in the upper chambers at the density of $2 \times 10^4$. The lower chamber was filled with medium containing 10% fetal bovine serum as the chemoattractant and incubated 24 h for migration assay and 48 h for the invasion assay, respectively. For migration assay, the number of cells on the lower surface of the membrane was counted in 5 fields under a microscope. For invasion assay, the upper chambers of the inserts were covered with Matrigel. After 48 h incubation, cells on the lower surface of the member was stained with 0.1% crystal violet. The number of cells on the lower surface of the membrane was counted in 5 fields under a microscope.

**Apoptosis.** NSCLC cells transfected as negative-siRNA or NACK-siRNA were collected and washed with PBS twice. After centrifugation, the cells were resuspended with 1X staining buffer at the dose of $1 \times 10^6$ cells/ml, then cells were dyed with 5 µl Annexin V-APC in the dark, at room temperature for 15 min. Flow cytometry was applied with FACSCalibur flow cytometer and analysis was performed with FlowJo software (Tree Star).

**Xenografts.** Four weeks old female nude mice were purchased from the Animal Center of The Fourth Military Medical University (Xi'an, China) and randomly divided into three groups with 10 per group, receiving subcutaneous injection of NACK-siRNA, negative-siRNA, or control cells, respectively. Of Tumor volume was measured using calipers every 4 days for 28 days and calculated as follows: Tumor size [volume (mm$^3$) = width$^2$ (mm)/2 x length (mm)]. Following 28-day post-inoculation, the animals were euthanized and the tumors were collected for further analyzing. The animal experiment was reviewed and approved by the Animal Care and Use Committee of the Second Affiliated Xi'an Jiaotong University (Xi'an, China).

**Statistical analysis.** All assays were repeated three times to insure reproducibility. The significance of results obtained from the control and treated groups were analyzed using the Student's t-test. The results are given as mean ± SD. $p<0.05$ was considered statistically significant.

**Results**

**Overexpression of NACK in NSCLC tumor tissues and cell lines.** The expression level of NACK in 35 NSCLC tissue samples and corresponding adjacent non-cancerous tissues were detected by the quantitative RT-PCR (qRT-PCR) and western blot assay. As shown in Fig. 1A and B, NACK was discovered highly expressed both at mRNA and protein levels in the NSCLC tissue samples compared with the paired adjacent normal tissues. Furthermore, the expression level of NACK was assessed in NSCLC cell lines (A549 and H1299) and NHBE, the result showed that NACK was greatly higher in A549 and H1299 cell lines than the normal cell line NHBE (Fig. 1A and C), indicating that NACK may play a positive role in NSCLC progression.

**High NACK expression is associated with different clinicopathological parameters.** To determine the potential role of
In the progress of NSCLC, the relationship between NACK expression and clinicopathological parameters in NSCLC cases were divided into two groups according to the mRNA level of NACK (low < median; high > median). The high expression of NACK was observed in 26/35 (74.29%) of NSCLC samples, and the expression of NACK was significantly correlated with the degree of differentiation (p=0.034), lymphatic metastasis (N stage) (p=0.007) and clinical stage (p=0.014) (Table I). However, the high level of NACK expression was not associated with gender, age, smoking, tumor size or histological type (p>0.05). Hence, NACK may be used as a potential unfavorable prognostic biomarker in NSCLC.

To investigate the correlation between NACK expression and the survival rates of NSCLC patients, Kaplan-Meier survival analysis was performed until the patients died or end of the research. Patients were divided into two groups depending on NACK expression level (low and high). We observed that the cumulative 4-year overall survival rate (OS) and decreased survival rate (DFS) of patients with high level of NACK detection were 30.7 and 34.6%, respectively, when compared to low NACK expression patients (77.8 and 77.8%, respectively) (Fig. 2). Hence, the level of NACK expression was an unfavorable predictive factor for prognosis of NSCLC patients.

Knockdown of NACK inhibits the expression of NACK in NSCLC cells. The efficient inhibition of NACK expression was examined by qRT-PCR and western blotting, the result showed that after transfected with NACK-siRNA, the expression of NACK was significantly decreased at mRNA level (Fig. 3A) and hardly observed at protein level (Fig. 3B) in A549 or H1299 cells. No significant difference was observed between negative-siRNA and control groups.

NACK is required for cell proliferation in NSCLC. Cell proliferation assay and cell invasion assay were performed in NSCLC cell lines A549 and H1299 with NACK knockdown by siRNA. CCK-8 assay verified that the cells transfected with NACK-siRNA showed a significant decrease in cell proliferation when compared with control group both in A549

Table I. Association between NACK expression and clinicopathological factors in patient with NSCLC.

<table>
<thead>
<tr>
<th>Variables</th>
<th>No. of cases</th>
<th>NACK expression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (%)</td>
<td>High (%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>19</td>
<td>5 (26.32)</td>
<td>14 (73.68)</td>
</tr>
<tr>
<td>Female</td>
<td>16</td>
<td>4 (25.00)</td>
<td>12 (75.00)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>24</td>
<td>5 (20.83)</td>
<td>19 (79.17)</td>
</tr>
<tr>
<td>≤60</td>
<td>11</td>
<td>4 (36.36)</td>
<td>7 (63.64)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>22</td>
<td>4 (18.18)</td>
<td>18 (81.82)</td>
</tr>
<tr>
<td>No</td>
<td>13</td>
<td>5 (38.46)</td>
<td>8 (61.54)</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;3</td>
<td>21</td>
<td>6 (28.57)</td>
<td>15 (71.43)</td>
</tr>
<tr>
<td>≤3</td>
<td>14</td>
<td>3 (21.43)</td>
<td>11 (78.57)</td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AC</td>
<td>26</td>
<td>6 (23.08)</td>
<td>20 (76.92)</td>
</tr>
<tr>
<td>SCC</td>
<td>7</td>
<td>2 (28.57)</td>
<td>5 (71.43)</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>1 (50.00)</td>
<td>1 (50.00)</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>11</td>
<td>4 (36.36)</td>
<td>7 (63.64)</td>
</tr>
<tr>
<td>Moderate</td>
<td>15</td>
<td>4 (26.67)</td>
<td>11 (73.33)</td>
</tr>
<tr>
<td>Poor</td>
<td>9</td>
<td>1 (11.11)</td>
<td>8 (88.89)</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1-2</td>
<td>23</td>
<td>6 (26.09)</td>
<td>17 (73.91)</td>
</tr>
<tr>
<td>T3-4</td>
<td>12</td>
<td>3 (25.00)</td>
<td>9 (75.00)</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>17</td>
<td>5 (29.41)</td>
<td>12 (70.59)</td>
</tr>
<tr>
<td>N1, 2, 3</td>
<td>18</td>
<td>4 (22.22)</td>
<td>14 (77.78)</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>21</td>
<td>5 (23.81)</td>
<td>16 (76.19)</td>
</tr>
<tr>
<td>III-IV</td>
<td>14</td>
<td>4 (28.57)</td>
<td>10 (71.43)</td>
</tr>
</tbody>
</table>

P-value *<0.05; **<0.01 statistically significant.
The colony formation assay was used to evaluate the tumor growth of transfected cells. Our data indicated that when A549 and H1299 cells were treated with NACK-siRNA, the growth of a transfected cell line. Our data indicated that when A549 and H1299 cells were treated with NACK-siRNA, the

(p<0.001) and H1299 (p<0.001) cells at the 5th day (Fig. 4A). The colony formation assay was used to evaluate the tumor growth of a transfected cell line. Our data indicated that when A549 and H1299 cells were treated with NACK-siRNA, the

Figure 3. Silencing of NACK suppresses the expression level of NACK in NSCLC cells. (A) mRNA levels of NACK in NACK knockdown cells detected by qRT-PCR. (B) Protein levels of NACK in NACK knockdown cells detected by western blot analysis. GAPDH was used as internal control. Data shown as mean ± SD of triplicate independent experiments. *p<0.01 when compared to negative-siRNA group.

Figure 4. Knockdown of NACK inhibited NSCLC cell proliferation and motility in vitro. (A) NACK-siRNA inhibited the proliferation of A549 and H1299 cells detected by CCK-8. (B) Photographs of colonies with Giemsa staining from A549 and H1299 cells treated with NACK silencing. (C) Statistical analysis of the number of colonies in A549 and H1299 cells with silenced NACK. (D) Effect of NACK silencing on the migration of A549 and H1299 cells. (E) Effect of NACK silencing on the invasion of A549 and H1299 cells. Data shown are the mean ± SD of triplicate independent experiments. *p<0.05 and ***p<0.001 when compared to negative-siRNA group.

(p<0.001) and H1299 (p<0.001) cells at the 5th day (Fig. 4A). The colony formation assay was used to evaluate the tumor growth of a transfected cell line. Our data indicated that when A549 and H1299 cells were treated with NACK-siRNA, the
ability of colony formation was remarkably decreased in A549 (p<0.05) and H1299 (p<0.05) cells (Fig. 4B and C).

**NACK knockdown inhibits the migration and invasion of NSCLC cells.** To investigate whether NACK regulates the migration and invasion of NSCLC cells, NSCLC cells were transfected with either NACK-siRNA or negative-siRNA. Cell migration and invasion were evaluated by using a Transwell insert. The results demonstrated that knockdown of NACK significantly reduced the number of migration at 24 h (p<0.01) and invasion at 48 h (p<0.01) (Fig. 4D and E), suggesting that NACK is necessary for NSCLC cell metastasis during the tumor progress.

**Induction of apoptosis by interference of NACK.** We further investigated whether interference NACK could induce apoptosis in A549 and H1299 cells. FITC assay results indicated that the apoptosis rates were significantly increased both in A549 and H1299 cells after knocking down NACK (Fig. 5). These results suggest the interference of NACK inhibits NSCLC progression through apoptosis induction in vitro.

**Knocking down NACK inhibits the transcriptional activity of Notch signaling pathway in NSCLC.** NACK was identified as a direct target gene of Notch pathway in human esophageal adenocarcinoma cells (15). Considering the specific action of the Notch pathway in different types of tumors, we investigated the role of NACK on the regulation of Notch pathway in NSCLC by transfecting NACK-siRNA into A549 and H1299 cells to knock down NACK expression. The results showed that the expression of the Notch target genes Hes1 and HeyL were reduced significantly at mRNA level (Fig. 6A). Western blot results also showed that transfection with NACK-siRNA reduced expression of Notch1, Hes1 and HeyL protein both in A549 and H1299 cells (Fig. 6B). Furthermore, as luciferase reporter assay result showed, co-transfection of NACK-siRNA with Hes1 reporter construct strongly reduced luciferase activity in both A549 and H1299 cells (Fig. 6C) when compared to the cells co-transfected with negative-siRNA. The data demonstrated that the transcriptional activity of Notch1 signaling pathway could be inhibited by knocking down the expression of NACK in NSCLC.

**Interference of NACK inhibits NSCLC progression in vivo.** To address whether changes of NACK expression could influence the growth of tumor in vivo, A549 and H1299 cells infected with negative-siRNA or NACK-siRNA were injected subcutaneously into the nude mice, and tumor size was measured every 4 days for 28 days. The results revealed that the knockdown of NACK inhibited tumorigenesis in vivo. The average tumor volume (Fig. 7A) and weight of mice (Fig. 7B and C) in NACK-siRNA group at day 28 was significantly decreased (p<0.01) compared to that of mice in control group. These results demonstrated that the interference of NACK inhibits NSCLC progression in vivo.

---

Figure 5. The effect of NACK silencing on cell apoptosis of A549 and H1299 cells. (A) Flow cytometric analysis of A549 and H1299 cells transfected with NACK-siRNA. (B) Percentage of apoptotic cells. Data are shown as the mean ± SD of triplicate independent experiments. **p<0.01 compared to the negative-siRNA group.
Discussion

Notch signaling is an evolutionarily conserved intercellular communication mechanism critical for cell survival, proliferation, differentiation, as well as maintaining stem cell quiescence and identity (16-18). Moreover, it has great relevance to multiple aspects of cancer biology, from cancer stem cells, angiogenesis to tumor immunity (19-23). Jiang et al., observed strong Notch-1 immunoreactivity in NSCLC, which correlated with Jagged-1 and VEGF expression (24). Under hypoxia, Notch-1 provides important survival signals to NSCLC cells (25). Baumgart et al., reported that Notch-1 also acts as a regulator of EGFR expression through incorporating with ADAM17 in NSCLC (26). Ji et al., discovered that Notch-1 downregulation inhibited cell growth and induced apoptosis in NSCLC by δ-tocotrienol (27). Furthermore, Notch-1 promoted NSCLC tumor progression through direct up-regulation of insulin-like growth factor 1 receptor (IGF1-R) (28) facilitating expression of the survivin (29).

NACK, a kind of atypical kinase (30), was first named Pragmin due to its ability to stimulate the activity of RhoA (31). Recently, Weaver et al., reported the crucial role of NACK as a novel regulator of Notch transcription and as the Notch-mediated tumor proliferation of mammary epithelial cells and esophageal adenocarcinoma cells (15). Therefore, we hypothesized that interference of NACK may inhibit the progression of NSCLC. Thus, the relationship between NACK expression and tumorigenesis of NSCLC is first demonstrated in this study.

Through detecting the expression of NACK in 35 tumor samples from NSCLC patients and analyzing their clinicopathological parameters, we found that NACK was remarkably over-expressed in NSCLC tumor tissues both at transcriptional and translational levels. Furthermore, high NACK expression was associated with tumor differentiation, lymphatic metastasis, clinical stage and poor survival prognosis in NSCLC patients, which indicated that NACK may be an independent prognostic factor for NSCLC.

RNA interference method as a powerful technology (32) was used in this study to knock down NACK expression. Cell indefinite proliferation, invasion and metastasis are the major causes of NSCLC occurrence (33). From in vivo and in vitro studies, we found that the interference of NACK markedly inhibited the proliferation, invasion and metastasis of NSCLC cells, indicating that NACK is necessary for the prolif-
KONG et al: SILENCING NACK INHIBITS TUMORIGENESIS IN NON-SMALL CELL LUNG CANCER BY Notch1 PATHWAY

Figure 7. NACK silencing inhibited tumorigenesis in vivo. (A) The curve of average tumor volume in nude mouse inoculation with A549 and H1299 cells treated with NACK-siRNA during the 28-day observation. (B) Representative images of tumors separated from each mouse group on day 28. (C) Average tumor weight in each group of nude mice on day 28. **p<0.01 when compared to negative-siRNA group.

Apoptosis plays a vital role in cancer development by the dysregulation of cell death and cell growth (34). Based on the flow cytometry assay, the interference of NACK significantly induces apoptosis rate in NSCLC cells, demonstrating that NACK may be a potential agent for the treatment of NSCLC (35,36).

Hes1 and HeyL, members of Hes and Hey families, respectively, have been reported as the direct downstream targets of the Notch1 signaling (37-39). In the present study, we found that their expression was markedly reduced when NACK was knocked down. Moreover, luciferase reporter assay also showed down-regulation of Notch1 signaling with NACK silencing in NSCLC cells. The Notch1 target genes Hes1 and HeyL are involved in regulating cell proliferation, apoptosis, differentiation and metabolism (40,41). Taken together, we hypothesized that the interference of NACK by siRNA inhibits tumorigenesis of NSCLC directly via targeting the Notch1 signaling pathway. However, the mechanisms of interference of NACK inhibiting tumorigenesis is not clear, and further research is necessary.

In conclusion, we provide the first evidence to demonstrate that NACK was robustly expressed in a subset of NSCLC samples and interference of NACK inhibits NSCLC progression through failing to activate Notch1 signaling complexes. Thus, NACK may be an attractive target to help develop novel therapeutic methods against NSCLC. Insightful studies are still needed to disclose other signaling pathways involved in regulating NSCLC.

Acknowledgements

We would like to thank Dr Xijing He and Dr Bin Zhou for their insightful comments and suggestions.

References